Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

10.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab: dreams, desperation and hope.

Nature reviews. Cancer·2024
Same author

Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.

Immunology·2022
Same author

Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors.

Cancer research·2021
Same author

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.

JCI insight·2019
Same author

The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44.

Oncotarget·2019
Same author

Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell.

JCI insight·2019

Related Experiment Video

Updated: Apr 5, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K

Reactivating p53 mutants selectively in patients.

Shuo Chen1, H Michael Shepard2, Min Lu3

  • 1Shanghai Immune Therapy Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.

Cancer Cell
|April 3, 2026
PubMed
Summary

Researchers are targeting the frequently mutated tumor suppressor protein p53, a key factor in cancer development. A new drug, rezatapopt, shows promise in reactivating a common p53 mutant, offering hope for future cancer therapies.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

336
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

11.6K

Related Experiment Videos

Last Updated: Apr 5, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

336
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

11.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • The tumor suppressor protein p53 is frequently inactivated across various cancers.
  • A wide spectrum of mutations affects p53 function.
  • Targeting specific p53 mutations is a critical area of cancer research.

Purpose of the Study:

  • To evaluate the potential of the reactivator drug rezatapopt.
  • To assess the efficacy of targeting a frequent p53 mutant.
  • To explore the clinical utility of p53 reactivation strategies.

Main Methods:

  • Utilized rezatapopt to target a specific, common p53 mutation.
  • Assessed the reactivation of the mutant tumor suppressor protein p53.
  • Evaluated the therapeutic implications in a cancer context.

Main Results:

  • Demonstrated the ability of rezatapopt to reactivate a frequent p53 mutant.
  • Provided evidence supporting the targeting of p53 mutants for cancer treatment.
  • Published findings in the New England Journal of Medicine.

Conclusions:

  • Rezataptop represents a promising therapeutic strategy for cancers with specific p53 mutations.
  • The reactivation of tumor suppressor protein p53 holds significant clinical potential.
  • Further development of p53-targeting agents is warranted for cancer therapy.